1. Williams RC, Paquette DW, Offenbacher S, et al. Treatment of periodontitis by local administration of minocycline microspheres: a controlled trial. J Periodontol 2001;72:1535-1544.
2. Goodson JM. Antimicrobial efficacy of Arestin in periodontitis therapy. Presented at the 35th Annual Meeting of the American Association for Dental Research; March 8-11, 2006; Orlando, FL.
3. Bland PS. Clinical efficacy and safety with ARESTIN® in patients with periodontitis. Presented at the 35th Annual Meeting of the American Association for Dental Research; March 8-11, 2006; Orlando, FL.
4. ARESTIN® (minocycline hydrochloride) 1 mg Microspheres [Prescribing Information]. Warminster, PA: OraPharma, Inc.; 2005.
5. Data on file. OraPharma, Inc., Warminster, PA; 2005.
6. Page RC. Periodontal diseases: a new paradigm. J Dent Educ 1998;62:812-821.
7. Socransky SS, Haffajee AD. Dental biofilms: difficult therapeutic targets. Periodontol 2000 2002;28:12-55.
8. Williams RC. Periodontal disease. N Engl J Med 1990;322:373-382.
9. Loesche WJ, Grossman NS. Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment. Clin Microbiol Rev 2001;14:727-752.
10. Albandar JM, Brunelle JA, Kingman A. Destructive periodontal disease in adults 30 years of age and older in the United States, 1988-1994. J Periodontol 1999;70:13-29.
11. American Dental Association. For the dental patient. Women and periodontal disease. J Am Dent Assoc 2002;133:671.
12. American Academy of Periodontology. Mouth body connection. Available at http://www.perio.org/consumer/mbc.top2.htm. Accessed October 11, 2006.
13. Paquette DW, Hanlon A, Lessem J, Williams RC. Clinical relevance of adjunctive minocycline microspheres in patients with chronic periodontitis: secondary analysis of a phase 3 trial. J Periodontal 2004;75:531-536.
14. Scannapieco FA. Periodontal inflammation: from gingivitis to systemic disease? Compend Contin Educ Dent 2004;25(suppl 1):16-25.
15. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL Jr. Microbial complexes in subgingival plaque. J Clin Periodontol 1998;25:134-144.
16. Levin RL. Periodontal profitability. Available at: http://www.dentaleconomics.com. Accessed December 28, 2005.
17. Blair C. The economic impact of the underdiagnosis of periodontal disease in general practice. Triage 2005;1:21-25.
18. American Dental Association, Survey Center. 1999 Survey of Dental Services Rendered. Chicago, IL: American Dental Association; 1999.
19. Meinberg TA, Barnes CM, Dunning DG, Reinhardt RA. Comparison of conventional periodontal maintenance versus scaling and root planing with subgingival minocycline. J Periodontol 2002;73:167-172.
20. O'Connor BC, Newman HN, Wilson M. Susceptibility and resistance of plaque bacteria to minocycline. J Periodontol 1990;61:228-233.
21. Dean JW, Branch-Mays GL, Hart TC, et al. Topically applied minocycline microspheres: why it works. Compendium 2003;24:247-257.
22. Ah MKB, Johnson GK, Kaldahl WB, Patil KD, Kalkwarf KL. The effect of smoking on the response to periodontal therapy. J Clin Periodontol 1994;21:91-97.
23. American Academy of Periodontology Research, Science and Therapy Committee. Tobacco use and the periodontal patient. J Periodontol 1999;70:1419-1427.
24. Fleischer HC, Mellonig JT, Brayer WK, Gray JL, Barnett JD. Scaling and root planing efficacy in multirooted teeth. J Periodontol 1989;60(7):402-409.
25. Preshaw PM, Hefti AF, Jepsen S, Etienne D, Walker C, Bradshaw MH. Subantimicrobial dose doxycycline as adjunctive treatment for periodontitis. A review. J Clin Periodontol 2004; 31:697-707.